ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Biotechnology

Healthcare
$3.69 -3.51%

-$0.35 today

Market cap
$370.95M
Beta
0.83
P/E (TTM)
-4.8
EPS (TTM)
-$1.99
52W Low $6.66High $18.90

Volume 1.70M

Average 1.67M

SPRY Interest Expense

Cost of servicing the company's debt during the period.

ARS Pharmaceuticals, Inc.NASDAQ: SPRY

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $2.44M, compared with $0 a year earlier. Trailing-twelve-month interest expense was $2.44M.

Context

  • Interest expense amounted to 3.1% of revenue in FY2025, up 3.1 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $2.44M or moves back toward the trailing-twelve-month quarterly average of $610.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.44M— QoQ
Last fiscal yearDec 2025
$2.6M— YoY
LTMMar 2026
$2.44M— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
2.6M USD
Year-over-year change
—
4-year CAGR
+122.5%

Interest Expense vs competitors

How SPRY compares with its peers on the latest reported figures

  • SPRY's LTM Mar 2026 interest expense of $2.44M is the lowest of the 4 companies compared; the peer median is $28.66M.
  • Interest expense amounts to 2.5% of revenue for SPRY, versus a peer median of 10.8%.
SPRY Competitors Peer median
Interest Expense for SPRY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MNKDMannKind CorporationLTM Mar 2026$39.11M -0.6%-17.7%10.8%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$28.66M -6.8%+27.3%9.1%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$16.76M -0.8%+11.2%33.3%
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$2.44M ——2.5%
Peer median (excluding SPRY) $28.66M-0.8%+11.2%10.8%

Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.51M1.32M30K89.15M84.28M
Cost of Revenue213K17.12M020.56M20.42M
Gross Profit5.29M(15.8M)30K68.59M63.86M
Gross Margin96.1%-1200.9%100.0%76.9%75.8%
Research & Development20.27M18.38M20.27M19.58M13.18M
Selling, General & Admin4.69M18.66M47.28M0230.12M
Operating Expenses24.75M19.71M67.55M71.68M243.3M
Depreciation & Amortization213K319K73K79K1.37M
EBITDA(19.92M)(34.36M)(54.29M)8.37M(167.41M)
EBITDA Margin-361.9%-2611.2%-180973.3%9.4%-198.6%
Operating Income(19.45M)(35.52M)(67.52M)(3.08M)(179.45M)
Operating Margin-353.3%-2698.8%-225066.7%-3.5%-212.9%
Interest Income800K00010.67M
Interest Expense106K0002.6M
Other Income / Expenses(789K)834K13.16M11.37M8.07M
Income Before Tax(20.24M)(34.68M)(54.37M)8.29M(171.38M)
Pre-Tax Margin-367.7%-2635.4%-181216.7%9.3%-203.3%
Income Tax Expense000288K(80K)
Net Income(20.24M)(34.68M)(54.37M)8M(171.3M)
Net Margin-367.7%-2635.4%-181216.7%9.0%-203.3%
EPS (Basic)(0.70)(0.87)(0.57)0.08(1.74)
EPS (Diluted)(0.70)(0.87)(0.57)0.08(1.74)
Weighted Avg Shares28.87M39.96M95.22M96.94M98.57M
Weighted Avg Shares (Diluted)28.87M39.96M95.22M102.39M98.57M

ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.